APA (7th ed.) Citation

Bond, S., Dunger, D., Wilson, M., Mander, A., Knip, M., Chhabra, A., . . . Schulte, A. M. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Bond, Simon, et al. Study Protocol: Minimum Effective Low Dose: Anti-human Thymocyte Globulin (MELD-ATG): Phase II, Dose Ranging, Efficacy Study of Antithymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes. BMJ Publishing Group.

MLA (9th ed.) Citation

Bond, Simon, et al. Study Protocol: Minimum Effective Low Dose: Anti-human Thymocyte Globulin (MELD-ATG): Phase II, Dose Ranging, Efficacy Study of Antithymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes. BMJ Publishing Group.